Rochelle R Maxwell1, Peter D Cole2,3. 1. The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Bronx, NY, 10467, USA. 2. The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Bronx, NY, 10467, USA. peter.cole@einstein.yu.edu. 3. Albert Einstein College of Medicine, 1225 Morris Park Avenue, Van Etten Building, Room VE 6A03, Bronx, NY, 10461, USA. peter.cole@einstein.yu.edu.
Abstract
PURPOSE OF REVIEW: The aim of this review is to summarize the most recent and most robust pharmacogenetic predictors of treatment-related toxicity (TRT) in childhood acute lymphoblastic leukemia (ALL). RECENT FINDINGS: Multiple studies have examined the toxicities of the primary chemotherapeutic agents used to treat childhood ALL in relation to host genetic factors. However, few results have been replicated independently, largely due to cohort differences in ancestry, chemotherapy treatment protocols, and definitions of toxicities. To date, there is only one widely accepted clinical guideline for dose modification based on gene status: thiopurine dosing based on TPMT genotype. Based on recent data, it is likely that this guideline will be modified to incorporate other gene variants, such as NUDT15. We highlight genetic variants that have been consistently associated with TRT across treatment groups, as well as those that best illustrate the underlying pathophysiology of TRT. In the coming decade, we expect that survivorship care will routinely specify screening recommendations based on genetics. Furthermore, clinical trials testing protective interventions may modify inclusion criteria based on genetically determined risk of specific TRTs.
PURPOSE OF REVIEW: The aim of this review is to summarize the most recent and most robust pharmacogenetic predictors of treatment-related toxicity (TRT) in childhood acute lymphoblastic leukemia (ALL). RECENT FINDINGS: Multiple studies have examined the toxicities of the primary chemotherapeutic agents used to treat childhood ALL in relation to host genetic factors. However, few results have been replicated independently, largely due to cohort differences in ancestry, chemotherapy treatment protocols, and definitions of toxicities. To date, there is only one widely accepted clinical guideline for dose modification based on gene status: thiopurine dosing based on TPMT genotype. Based on recent data, it is likely that this guideline will be modified to incorporate other gene variants, such as NUDT15. We highlight genetic variants that have been consistently associated with TRT across treatment groups, as well as those that best illustrate the underlying pathophysiology of TRT. In the coming decade, we expect that survivorship care will routinely specify screening recommendations based on genetics. Furthermore, clinical trials testing protective interventions may modify inclusion criteria based on genetically determined risk of specific TRTs.
Authors: Shinji Kishi; Cheng Cheng; Deborah French; Deqing Pei; Soma Das; Edwin H Cook; Nobuko Hijiya; Carmelo Rizzari; Gary L Rosner; Tony Frudakis; Ching-Hon Pui; William E Evans; Mary V Relling Journal: Blood Date: 2007-01-30 Impact factor: 22.113
Authors: Gabriele Stocco; Wenjian Yang; Kristine R Crews; William E Thierfelder; Giuliana Decorti; Margherita Londero; Raffaella Franca; Marco Rabusin; Maria Grazia Valsecchi; Deqing Pei; Cheng Cheng; Steven W Paugh; Laura B Ramsey; Barthelemy Diouf; Joseph Robert McCorkle; Terreia S Jones; Ching-Hon Pui; Mary V Relling; William E Evans Journal: Hum Mol Genet Date: 2012-07-30 Impact factor: 6.150
Authors: Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton Journal: Br J Clin Pharmacol Date: 2016-06-30 Impact factor: 4.335
Authors: M Krajinovic; J Elbared; S Drouin; L Bertout; A Rezgui; M Ansari; M-J Raboisson; S E Lipshultz; L B Silverman; S E Sallan; D S Neuberg; J L Kutok; C Laverdière; D Sinnett; G Andelfinger Journal: Pharmacogenomics J Date: 2015-09-08 Impact factor: 3.550
Authors: Clara Vicente-Garcés; Elena Esperanza-Cebollada; Sara Montesdeoca; Montserrat Torrebadell; Susana Rives; José Luis Dapena; Albert Català; Nuria Conde; Mireia Camós; Nerea Vega-García Journal: Front Mol Biosci Date: 2022-04-07